Magrolimab
- Generic Name
- Magrolimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2169232-81-7
- Unique Ingredient Identifier
- 90YIEHRFJ9
- Background
Magrolimab is under investigation in clinical trial NCT02953782 (Trial of Magrolimab (Hu5f9-g4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer).
- Associated Conditions
- -
- Associated Therapies
- -
Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
Phase 1
Active, not recruiting
- Conditions
- Urothelial CarcinomaBladder Cancer
- Interventions
- First Posted Date
- 2019-03-11
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 272
- Registration Number
- NCT03869190
- Locations
- 🇫🇷
Centre Francois Baclesse, Caen, France
🇬🇷Attiko Hospital University of Athens, Athens, Greece
🇬🇷Athens Medical Center, Athens, Greece
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath